Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

PubWeight™: 6.28‹?› | Rank: Top 1%

🔗 View Article (PMID 14652239)

Published in J Natl Cancer Inst on December 03, 2003


Rolando Herrero1, Xavier Castellsagué, Michael Pawlita, Jolanta Lissowska, Frank Kee, Prabda Balaram, Thangarajan Rajkumar, Hema Sridhar, Barbara Rose, Javier Pintos, Leticia Fernández, Ali Idris, María José Sánchez, Adoración Nieto, Renato Talamini, Alessandra Tavani, F Xavier Bosch, Ulrich Reidel, Peter J F Snijders, Chris J L M Meijer, Raphael Viscidi, Nubia Muñoz, Silvia Franceschi, IARC Multicenter Oral Cancer Study Group

Author Affiliations

1: International Agency for Research on Cancer, Lyon, France. rherrero@

Associated clinical trials:

Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity | NCT01525927

Articles citing this

(truncated to the top 100)

Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10

The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39

Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev (2004) 3.52

Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2009) 3.33

Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00

Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91

Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine (2008) 2.13

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03

Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. Am J Epidemiol (2009) 1.97

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol (2014) 1.83

Analysis of the effect of DNA purification on detection of human papillomavirus in oral rinse samples by PCR. J Clin Microbiol (2005) 1.81

Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76

Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol (2006) 1.76

Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A (2005) 1.74

Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood (2005) 1.73

Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71

Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res (2011) 1.70

Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol (2009) 1.70

A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet (2011) 1.68

Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev (2011) 1.68

MicroRNA profiling and head and neck cancer. Comp Funct Genomics (2009) 1.68

Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A (2006) 1.57

Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol (2012) 1.45

Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer (2011) 1.41

Involvement of DNMT 3B promotes epithelial-mesenchymal transition and gene expression profile of invasive head and neck squamous cell carcinomas cell lines. BMC Cancer (2016) 1.40

Incidence and survival trends of lip, intra-oral cavity and tongue base cancers in south-east England. Ann R Coll Surg Engl (2015) 1.39

Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev (2016) 1.38

Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications. J Dent Res (2009) 1.31

Family history of cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer (2009) 1.30

Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol (2012) 1.29

Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol (2012) 1.27

Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25

Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men. P R Health Sci J (2010) 1.22

MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas. J Oral Maxillofac Res (2013) 1.22

Histologic identification of human papillomavirus (HPV)-related squamous cell carcinoma in cervical lymph nodes: a reliable predictor of the site of an occult head and neck primary carcinoma. Head Neck Pathol (2008) 1.22

Cellular binding partners of the human papillomavirus E6 protein. Arch Virol (2008) 1.21

Replication and assembly of human papillomaviruses. J Dent Res (2009) 1.20

The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol (2006) 1.20

Type of alcoholic beverage and risk of head and neck cancer--a pooled analysis within the INHANCE Consortium. Am J Epidemiol (2008) 1.19

Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol (2014) 1.19

Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev (2009) 1.18

Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Int J Epidemiol (2010) 1.18

Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol (2009) 1.16

Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system. Head Neck Pathol (2010) 1.16

Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer (2011) 1.14

11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer (2006) 1.14

Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One (2012) 1.14

Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer (2011) 1.13

Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med (2010) 1.09

Concern The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol (2012) 1.09

InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst (2012) 1.09

Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res (2010) 1.09

Association of p73 G4C14-to-A4T14 polymorphism with human papillomavirus type 16 status in squamous cell carcinoma of the head and neck in non-Hispanic whites. Cancer (2009) 1.09

Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health (2008) 1.09

Human papillomavirus molecular biology and disease association. Rev Med Virol (2015) 1.09

Recurrent respiratory papillomatosis: an overview of current thinking and treatment. Eur Arch Otorhinolaryngol (2007) 1.08

Role of human papillomavirus and its detection in potentially malignant and malignant head and neck lesions: updated review. Head Neck Oncol (2009) 1.07

The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol (2008) 1.06

Screening for high risk human papilloma virus (HR-HPV) subtypes, among Sudanese patients with oral lesions. Int J Clin Exp Med (2013) 1.06

No role for human papillomavirus in esophageal squamous cell carcinoma in China. Int J Cancer (2010) 1.06

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer (2008) 1.06

Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res (2009) 1.06

Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses (2015) 1.06

Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis. Clin Cancer Res (2011) 1.06

Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital (2009) 1.05

Controversies surrounding human papilloma virus infection, head & neck vs oral cancer, implications for prophylaxis and treatment. Head Neck Oncol (2009) 1.04

Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle (2013) 1.04

The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview. Infect Agent Cancer (2011) 1.04

The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer (2007) 1.03

Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study. Infect Agent Cancer (2011) 1.01

Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals. Curr Opin Oncol (2013) 1.01

Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol (2011) 1.01

Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience (2015) 1.00

Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. Int J Cancer (2014) 0.99

Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer. Clin Cancer Res (2010) 0.99

High-risk human papillomavirus (HPV) screening and detection in healthy patient saliva samples: a pilot study. BMC Oral Health (2011) 0.98

A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment. J Cancer Res Clin Oncol (2009) 0.98

Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue. J Clin Microbiol (2005) 0.97

Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma. PLoS One (2012) 0.97

Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995-2005. PLoS One (2012) 0.97

Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genet Med (2008) 0.97

High risk HPV types 18 and 16 are potent modulators of oral squamous cell carcinoma phenotypes in vitro. Infect Agent Cancer (2007) 0.96

Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? Cancer Epidemiol Biomarkers Prev (2008) 0.96

Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use. Ann Oncol (2008) 0.96

Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol (2009) 0.96

Alcohol, smoking and human papillomavirus in laryngeal carcinoma: a Nordic prospective multicenter study. J Cancer Res Clin Oncol (2007) 0.95

Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol (2011) 0.95

An examination of male and female odds ratios by BMI, cigarette smoking, and alcohol consumption for cancers of the oral cavity, pharynx, and larynx in pooled data from 15 case-control studies. Cancer Causes Control (2011) 0.94

Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. Virol J (2010) 0.94

Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94

The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. J Virol (2008) 0.94

Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology (2007) 0.94

Low prevalence of human papillomavirus in oral cavity carcinomas. Head Neck Oncol (2010) 0.93

Impact of HPV in Oropharyngeal Cancer. J Oncol (2010) 0.93

Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis (2008) 0.92

Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. Int J Epidemiol (2015) 0.91

Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J Clin Oncol (2015) 0.91

Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med (2014) 0.91

Articles by these authors

Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67

Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23

Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39

A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10

WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14

Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86

Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet (2007) 8.55

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30

Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis (2007) 6.86

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 6.69

Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61

Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med (2010) 6.04

Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99

Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87

Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79

GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57

Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09

Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82

Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54

Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38

Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. Am J Respir Crit Care Med (2010) 4.35

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31

A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer (2009) 4.28

Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18

Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14

Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98

Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86

Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81

Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS (2006) 3.76

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72

Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69

Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67

Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64